Santiago Treviño

Santiago Treviño

Auto-generated profile, based on publicly available information

Santiago Treviño

The University of Texas MD Anderson Cancer Center 1 Department of Thoracic/Head and Neck Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NVNatalie I. Vokes
Natalie I. Vokes
ACAna Galan Cobo
Ana Galan Cobo
MFMargarita Fernandez-Chas
Margarita Fernandez-Chas
DMDavid Molkentine
David Molkentine
STSantiago Treviño
Santiago Treviño
JHJohn V. Heymach
John V. Heymach
Purpose: Ataxia-telangiectasia mutated (ATM) is the most frequently mutated DNA damage repair gene in non–small cell lung cancer (NSCLC). However, the molecular correlates of ATM mutations and their clinical implications have not been fully elucidated. Experimental Design: Clinicopathologic and genomic data from 26,587 patients with NSCLC from MD Anderson, public databases, and a de-identified nationwide (US-based) NSCLC clinicogenomic database (CGDB) were used to assess the co-mutation landscape, protein expression, and mutational processes in ATM-mutant tumors. We used the CGDB to evaluate ATM-associated outcomes in patients treated with immune checkpoint inhibitors (ICI) with or without chemotherapy, and assessed the effect of ATM loss on STING signaling and chemotherapy sensitivity in preclinical models. Results: Nonsynonymous mutations in ATM were observed in 11.2% of samples (2,980/26,587) and were significantly associated with mutations in KRAS, but mutually exclusive with EGFR (q < 0.1). KRAS mutational status constrained the ATM co-mutation landscape, with strong mutual exclusivity with TP53 and KEAP1 within KRAS-mutated samples. Those ATM mutations that co-occurred with TP53 were more likely to be missense mutations and associate with high mutational burden, suggestive of non-functional passenger mutations. In the CGDB cohort, dysfunctional ATM mutations associated with improved OS only in patients treated with ICI-chemotherapy, and not ICI alone. In vitro analyses demonstrated enhanced upregulation of STING signaling in ATM knockout cells with the addition of chemotherapy. Conclusions: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.

27 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
NVNatalie I. Vokes
Natalie I. Vokes
JSJessica L. Symons
Jessica L. Symons
BRBrooke Rhead
Brooke Rhead
LHLingzhi Hong
Lingzhi Hong
PSPooja Shah
Pooja Shah
JRJordi A. Rodon
Jordi A. Rodon
Purpose: Homozygous deletion of the 9p21 locus, containing CDKN2A/B and MTAP [CDKN2A/MTAP deletion (CMdel)], underlies emerging therapeutic strategies, including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcome associations of CMdel in non–small cell lung cancer (NSCLC) remain incompletely defined. Experimental Design: We analyzed Tempus Lens records with paired DNA (xT) and RNA (xR) sequencing. After quality filtering (purity ≥40%), 16,947 patients were included in the primary dataset, and 10,996 were included in the validation dataset and stratified by deletion status [CMdel vs. CM wild-type (CMwt)]. IFN status was defined by IFN-kappa (IFNK) expression [log2(TPM + 1)] using the 25th percentile of CMwt as the threshold. Immune composition was inferred by quanTIseq. First-line regimens were grouped as immune checkpoint inhibitor (ICI) monotherapy, ICI chemotherapy, chemotherapy, or tyrosine kinase inhibitors (TKI). Best response and time to next treatment (TTNT) with risk-set adjustment and 18-month truncation were assessed. Results: CMdel occurred in 11.7% (n = 1,991) and 15% (n = 1,676), respectively, and was enriched in mucinous histology, stage IV disease, and never smokers. CMdel was associated with EGFR, TERT, and SMARCA4 alterations, whereas CMwt was associated with RB1, SETD2, and ARID2. More than 50% of CMdel tumors harbored targetable coalterations, enriched in EGFR/ALK/RET and relatively depleted in KRAS. CMdel tumors exhibited lower PD-L1, mutation burden, and immune infiltration. TTNT did not differ by CM status for ICI monotherapy or TKI but was shorter in CMdel for ICI chemotherapy and chemotherapy. Discordant and broad deletions were less common and had weaker TTNT association. IFNK-low expression marked immune-excluded subgroups with worse treatment outcomes. Conclusions: CDKN2A/MTAP loss defines a prevalent, genomically distinct NSCLC subset enriched in actionable drivers. CMdel associates with worse outcomes to ICI/chemotherapy-containing regimens. These findings highlight convergent biology at 9p21 and support biomarker-guided development of PRMT5/MAT2A inhibitors in MTAP-deleted NSCLC.

17 December 2025
Verified
Other
Open access
NVNatalie I. Vokes
Natalie I. Vokes
ACAna Galan Cobo
Ana Galan Cobo
MFMargarita Fernandez-Chas
Margarita Fernandez-Chas
DMDavid Molkentine
David Molkentine
STSantiago Treviño
Santiago Treviño
JHJohn V. Heymach
John V. Heymach
Supp Figure 10. ATM loss enhances STING signaling activation with chemotherapy in human cell lines.

17 December 2025
Verified
Other
Open access
NVNatalie I. Vokes
Natalie I. Vokes
ACAna Galan Cobo
Ana Galan Cobo
MFMargarita Fernandez-Chas
Margarita Fernandez-Chas
DMDavid Molkentine
David Molkentine
STSantiago Treviño
Santiago Treviño
JHJohn V. Heymach
John V. Heymach
Supp Table 4. ATM co-mutation enrichment analysis in KRAS wild-type tumors, in meta-analysis and within individual cohorts.

17 December 2025
Verified
Other
Open access
NVNatalie I. Vokes
Natalie I. Vokes
ACAna Galan Cobo
Ana Galan Cobo
MFMargarita Fernandez-Chas
Margarita Fernandez-Chas
DMDavid Molkentine
David Molkentine
STSantiago Treviño
Santiago Treviño
JHJohn V. Heymach
John V. Heymach
Supp Table 3. ATM co-mutation enrichment analysis in KRAS mutant tumors, in meta-analysis and within individual cohorts.

17 December 2025
Verified
Other
Open access
NVNatalie I. Vokes
Natalie I. Vokes
ACAna Galan Cobo
Ana Galan Cobo
MFMargarita Fernandez-Chas
Margarita Fernandez-Chas
DMDavid Molkentine
David Molkentine
STSantiago Treviño
Santiago Treviño
JHJohn V. Heymach
John V. Heymach
Supp Figure 1. Cohort Selection and distribution of ATM mutation class.